Industry News

Biotechnology Industry News

Corbus Pharmaceuticals’ phase 1b…

September 14th, 2026|FierceBiotech|

Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biotech plans to enter phase 2.

Electra Therapeutics is hoping to…

September 14th, 2026|FierceBiotech|

Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug ipsoprubart.

Cellectis may have kicked off the…

September 14th, 2026|FierceBiotech|

Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.

MediLink has reported phase 3…

September 14th, 2026|FierceBiotech|

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survival fell short of the bar set by GSK’s

Definium Therapeutics has scored a…

September 11th, 2026|FierceBiotech|

Definium Therapeutics has scored a third straight phase 3 win for its LSD formula, with the psychedelic significantly alleviating anxiety symptoms and setting up an FDA filing next year.

Cullinan Therapeutics and Taiho…

September 11th, 2026|FierceBiotech|

Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the front-line setting.

After decades of hard-won…

September 11th, 2026|FierceBiotech|

After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full heterogeneity of the disease.

Revolution Medicines recently made…

September 11th, 2026|FierceBiotech|

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

BioNTech has linked gotistobart to…

September 11th, 2026|FierceBiotech|

BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.

GSK’s risvutatug rezetecan has…

September 11th, 2026|FierceBiotech|

GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.

The FDA has put enrollment in…

September 10th, 2026|FierceBiotech|

The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million deal.

Frazier Life Sciences (FLS) has…

September 10th, 2026|FierceBiotech|

Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.

It may have seemed like an…

September 9th, 2026|FierceBiotech|

It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based biotech trade group was playing host

Following a steady stream of…

September 9th, 2026|FierceBiotech|

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.